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The genes encoding ATP-binding cassette (ABC) transporters
occupy 2.5% of the genome of Mycobacterium tuberculosis.
However, none of these putative ABC transporters has been
characterized so far. We describe the development of expression
systems for simultaneous expression of the ATP-binding protein
DrrA and the membrane integral protein DrrB which together
behave as a functional doxorubicin efflux pump. Doxorubicin
uptake in Escherichia coli or Mycobacterium smegmatis ex-
pressing DrrAB was inhibited by reserpine, an inhibitor of ABC
transporters. The localization of DrrA to the membrane de-
pended on the simultaneous expression of DrrB. ATP binding
was positively regulated by doxorubicin and daunorubicin. At
the same time, DrrB appeared to be sensitive to proteolysis when
expressed alone in the absence of DrrA. Simultaneous expression
INTRODUCTION
Mycobacterium tuberculosis accounts for the largest number of
deaths caused by a single human pathogen with predictions of an
excess of 80 million new cases and 20 million deaths in the
coming decade. The appearance of drug-resistant strains of M.
tuberculosis and the HIV pandemic have exacerbated this situ-
ation. Effective treatment of tuberculosis infections requires the
identification of new drugs, drug targets and drug-resistance
factors. The ATP-binding cassette (ABC) transporters [1] con-
stitute a large superfamily of multi-subunit permeases that
transport diverse molecules (ions, amino acids, peptides, drugs,
antibiotics, lipids, polysaccharides, proteins etc.) at the expense
of ATP [2,3]. The genes encoding the ABC transporters occupy
about 2.5% of the genome of M. tuberculosis [4]. At least 37
complete and incomplete ABC transporters have been identified
in M. tuberculosis based on the structural similarities of the
typical subunits of ABC transporters present in all living organ-
isms. Knowledge of these M. tuberculosis ABC transporters is
necessary both for understanding their involvement in the
development of multidrug resistance in M. tuberculosis as well as
in the export of the unique antigenic cell-surface components
of this organism, such as the phthiocerol mycocerosates and
lipoarabinomannan.
The prototype eukaryotic ABC transporter is P-glycoprotein
[5]. The 170 kDa P-glycoprotein is characterized by two mem-
brane integral domains with six membrane-spanning helices each
connected with two ATP-hydrolysing domains and the presence
of ‘Walker sites A and B’ [6] in the primary structure of the ATP-
hydrolysing domains, which, by analogy with ATP-and GTP-
Abbreviations used: ABC, ATP-binding cassette ; BCECF-AM, 2«,7«-bis-(2-carboxyethyl)-5(6)-carboxyfluorescein acetomethoxyl ester ; DIM,
phthiocerol dimycocerosate ; IPTG, isopropyl b-D-thiogalactoside ; MIC, minimum inhibitory concentration.
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of the two polypeptides was essential to obtain a functional
doxorubicin efflux pump. Expression of DrrAB in E. coli
conferred 8-fold increased resistance to ethidium bromide, a
cationic compound. 2«,7«-bis-(2-Carboxyethyl)-5(6)-carboxyfluo-
rescein (BCECF), a neutral compound, also behaved as a sub-
strate of the reconstituted efflux pump. When expressed in
M. smegmatis, DrrAB conferred resistance to a number of clini-
cally relevant, structurally unrelated antibiotics. The resistant
phenotype could be reversed by verapamil and reserpine, two
potent inhibitors of ABC transporters.
Key words: antibiotic resistance, efflux pump, lipid transporter,
mycobacteria, virulence.
binding proteins, bind nucleotides [7,8]. The doxorubicin-
resistance operon, first identified in Streptomyces peucetius [9],
shares similarity with the eukaryotic P-glycoprotein. Two trans-
lationally coupled open reading frames, drrA and drrB, encode
an ABC-type transporter, with drrA encoding the nucleotide-
binding domain and drrB encoding the membrane integral
component [10]. A monomer of DrrA and DrrB forms a molecule
about half the size of P-glycoprotein. The likely stoichiometry
of the functional transporter is DrrA
#
B
#
[10]. By analogy to
S. peucetius, the completed M. tuberculosis genome [11] also
contains a doxorubicin-resistance operon, drr. In addition, the
drr operon has been identified in the genomes of Mycobacterium
leprae and Mycobacterium aium. As powerful techniques of
molecular biology have become available, the drr operon has
assumed particular significance in relation to its implications in
the virulence of M. tuberculosis. The biosynthesis of phthiocerol
dimycocerosates (DIMs) involves several genes [12]. The genes
pps A-E encode a type I modular polyketide synthase responsible
for the synthesis of phthiocerol and phenolphthiocerol. Another
gene, mas, encodes an iterative type I polyketide synthase that
produces mycocerosic acid. The gene fadD28 is probably involved
in the release and transfer of mycocerosic acid from Mas on to the
diols. These seven genes are clustered on a 50 kb fragment of
the chromosome containing, among other genes, the open reading
frames of the drr operon and mmpl7, encoding polypeptides
similar to ABC transporters. Signature-tagged transposon muta-
genesis has shown that transposon insertions in the drr operon or
mmpl7 lead to a strong growth defect of M. tuberculosis in the
lungs of intravenously infected mice [13,14] and in export of
DIM to the cell surface [15].
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The biochemical characterization of the Drr transporter
assumes obvious importance in the light of these recent observa-
tions. Its association with virulence suggests that it presents an
attractive drug target, which if inactivated will probably disable
the pathogen in terms of its ability to export complex molecules
such as DIM, a surface-exposed antigenic lipid present in seven
pathogenic species of mycobacteria [16], to the cell surface. In
addition, the likely importance of the drr operon in multidrug
resistance deserves evaluation. The biochemical characterization
of the drr operon was undertaken before most of these recent
observations came to light, envisaging its likely importance in
multidrug resistance of M. tuberculosis. The goal was to develop
expression systems expressing a functional DrrAB transporter in
order to evaluate the role of the transporter in drug resistance as
well as to exploit the expression systems in further characteriz-
ation of the transporter in relation to the roles of the conserved
domains in transport function.
EXPERIMENTAL
Materials
["%C]Doxorubicin and the Thermosequenase cycle sequencing kit
were purchased from Amersham Bioscience (Little Chalfont,
Bucks., U.K.). Restriction enzymes and antibiotics were pur-
chased from Life Technologies (Gaithersberg, MD, U.S.A.), [a-
$#P]ATP was purchased from NEN Life Sciences (Boston, MA,
U.S.A.) and 2«,7«-bis-(2-carboxyethyl)-5(6)-carboxyfluorescein
acetomethoxyl ester (BCECF-AM) was a product of Molecular
Probes (Eugene, OR, U.S.A.). Doxorubicin, daunorubicin,
ethidium bromide, reserpine, verapamil, chloramphenicol, tetra-
cycline, erythromycin, ethambutol, rifampicin, norfloxacin,
streptomycin and puromycin were products of Sigma Chemicals
(St. Louis, MO, U.S.A.). All other reagents were of analytical
grade.
Strains
Cloning was performed in Escherichia coli DH5a. E. coli
LMG194 (Invitrogen) and E. coli BL21(DE3) (Novagen) were
used for protein expression. Mycobacterium smegmatis mc#155
has been described by Snapper et al. [17].
Amplification and cloning of drrAB from cosmid MTCY19H9
The drrAB operon was amplified from the cosmid MTCY19H9
(a kind gift from Stewart Cole, Institut Pasteur, Paris, France)
using the primer pair 5«-CGGGGTACCATATGCGCAACGA-
CGACATGGC-3« (sense) and 5«-CCCGAATTCGTCGTGAT-
CATGGGCCGCCTAG-3« (antisense) with asymmetric KpnI
and EcoRI sites (underlined) in the sense and antisense primers
respectively. The PCR product was digested with KpnI
and EcoRI, cloned into the vector pUC19 between the KpnI and
EcoRI sites to generate the plasmid pCKB101, and sequenced on
both strands. The sequenced drrAB gene was excised from
pUC19 and cloned between the NdeI (indicated above in bold)
and EcoRI sites of the expression vector pET 28a+ (Novagen) to
give the plasmid pCKB102.
Cloning of the drrA and drrB genes
The drrA gene was amplified from plasmid pCKB101 using the
following primer pair : 5«-CGGGGTACCATATGCGCAACG-
ACGACATGGC-3« (sense) and 5«-ATAGAATTCATCGCGC-
GGACCCCGACACCAG-3« (antisense) with asymmetric KpnI
and EcoRI sites, and cloned into the vector pK18 [18] between
the KpnI and EcoRI sites (underlined) to generate the plasmid
pCKB104. pCKB104 was sequenced and the drrA gene was
excised and cloned between the NdeI (shown above in bold) and
EcoRI sites of pET28a+ to give pCKB105.
The drrB gene was amplified from plasmid pCKB101 using the
following primer pair : 5«-GAAGATCTCATATGAGCGGCC-
CG-3« (sense) and 5«-CCCGAATTCGTCGTGATCATGGGC-
CGCCTAG-3« (antisense) with asymmetric BglII and EcoRI
sites, cloned in the vector pK18 to give pCKB107 and sequenced.
The drrB gene was excised and cloned between the NdeI and
EcoRI sites of pET28a+ to give pCKB108, as well as between
the BglII and EcoRI sites of pBAD-HisA to give pCKB109.
Construction of an artificial operon
pCKB108 was digested with NcoI and NdeI to eliminate a 58 bp
fragment. This was replaced by oligonucleotide 5«-CATGGCT-
GGTACCGGGGTCAAGGAGATAACA-3« and its reverse
complement strand, with overhangs of CATG at the 5«-end and
AT at the 3« end to complement NcoI and NdeI respectively. The
resulting plasmid, termed pCKB110, contained a KpnI site
(underlined) and a Shine–Dalgarno sequence (AGGA).
The drrA gene was amplified from pCKB105 using the primers
5«-GAAGATCTCATATGCGCAACGACGACATGGC-3«
(sense) and 5«-GGAATTCGGTACCAGATGGGTCAGAGA-
CTCGGT-3« (antisense) with asymmetric NdeI and EcoRI sites
and cloned between the NdeI and EcoRI sites of pET28a+ to give
pCKB111. Plasmid pCKB110 was digested with KpnI and EcoRI
and the fragment containing the drrB gene with the upstream
Shine–Dalgarno sequence was cloned between the KpnI (shown
above in bold) and EcoRI sites of pCKB111 to give pCKB112.
pCKB112 therefore contains the translationally coupled drrAB
genes, with the artificial ribosome-binding site AGGA upstream
of the drrB gene, under the control of the T7 promoter.
The following cloning steps were performed to introduce the
Myc epitope at the C-terminal end of DrrB. Using pCKB112 as
a template, the drrA and drrB genes were amplified using the
primer pair 5«-GAAGATCTCATATGCGCAACGACGACA-
TGGC-3« (sense ; primer DrrA-His) and 5«-AAAAAGCTTTG-
GCCGCCTAGCCAAAACGTTTTGGCTAGGCGGCCA-3«
(antisense ; BglII and HindIII sites in the sense and antisense
primers are underlined) and cloned between the BglII and HindIII
sites of pBAD myc HisA to give plasmid pCKB113 carrying a
translational fusion of the Myc epitope to the C-terminal end of
DrrB. Primer DrrA-His was used as the sense primer paired with
the antisense primer 5«-ATGGAATTCTCAGTCGACGGCGC-
TATTCAGATC-3« (EcoRI site underlined) for amplification
using pCKB113 as the template, and the product was cloned
between the BamHI and EcoRI sites of pET28a+ to give
pCKB114. pCKB114 carried the drrA gene fused to an upstream
sequence encoding a hexahistidine tag, and the drrB gene fused
to a downstream sequence encoding a Myc epitope. Further
cloning was performed to place the His-drrA-drrB-myc-encoding
sequence under the control of the mycobacterial Hsp60 promoter
in a shuttle vector with E. coli and mycobacterial origins of
replication (derived from pYUB12) [17] and a kanamycin-
resistance marker, generating the plasmid pCKB115.
Expression of proteins in E. coli
Recombinant plasmids derived from pET28a+ were transformed
in E. coli BL21(DE3). Cells were grown to mid-logarithmic phase
(D
’!!
fl 0.6) in Luria broth and induction was carried out at
different temperatures with different concentrations of isopropyl
b-d-thiogalactoside (IPTG). Recombinant plasmids derived from
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pBad-HisA were transformed into E. coli LMG194 cells (In-
vitrogen pBAD manual) and induced with varying concen-
trations of arabinose at different temperatures.
Expression of proteins in M. smegmatis mc2155
Electroporation of M. smegmatis mc#155 with the plasmid
pCKB115 was performed as described by Larsen [19]. Transfor-
mants were grown in Luria broth supplemented with 25 lg}ml
kanamycin up to a D
’!!
value of 0.8, followed by heat shock.
Fractionation of cells and localization of proteins
After induction E. coli cells were suspended in 10 mM Tris}HCl
(pH 7.4), 1 mM MgCl
#
, 1 mM PMSF, 20 lg}ml leupeptin,
10 lg}ml pepstatin and 10 lg}ml aprotinin, and sonicated thrice
at 200 W for 15 s. The unbroken cells were removed by centri-
fugation at 500 g for 5 min. Inclusion bodies were obtained by
centrifugation at 5000 g for 5 min. Membranes were obtained
by centrifugation at 100000 g for 60 min, and the supernatant
constituted the cytosolic extract. Membranes from M. smegmatis
transformants were prepared as described by Basu et al. [20].
ATP-binding experiment
Photolabelling of membranes was carried out with [a-$#P]ATP
(Easytides ;NEN) at varying concentrations and a specific activity
of 0.25 mCi}mmol in 10 mM Tris}HCl, pH 7.4, containing
10 mM dithiothreitol. Where indicated, doxorubicin was added
to the reaction mixture to a final concentration of 50 or 100 lM
and MgCl
#
was added to a final concentration of 5 mM. The
reaction was carried out in a volume of 25 ll in a 96-well
microtitre plate kept on a block of ice directly under UV
illumination (254 nm) for 30 min. Samples were analysed by
SDS}PAGE and autoradiography.
Minimum inhibitory concentrations (MICs)
E. coli BL21(DE3)}pCKB114 or M. smegmatis}pCKB115 were
induced as described above to express DrrA and DrrB. MICs
were determined by the broth microdilution method according to
National Committee for Clinical Laboratory Standards guide-
lines [21]. Cells were added at 10’ colony-forming units}ml in
microtitre wells (in duplicate) containing serial dilutions of
different drugs. Controls without drug were also run. The plate
was incubated at 37 °C overnight (for E. coli) or 48 h (for
M. smegmatis). MIC was defined as the lowest concentration of
drug with complete absence of growth (A
’!!
" 0.05, i.e. a value
equal to visible growth). Each MIC was determined at least
thrice using three different transformants.
Uptake of [14C]doxorubicin
Cells expressing DrrA and DrrB were grown up to mid-
logarithmic phase, induced, harvested and suspended to a D
’!!
value of 20 in 50 mM potassium phosphate, pH 7.4, containing
5 mM MgSO
%
. Uptake was initiated (in the absence or presence
of inhibitors) by the addition of doxorubicin (5 lM; 10–
50 lCi}mmol). Cells were diluted into ice-cold 10 mM potassium
phosphate, pH 7.4, containing 0.1 M LiCl, filtered on glass fibre
(Whatman GF}C) filters, dried and counted in a liquid scin-
tillation counter.
Uptake of BCECF-AM
This was done as described by Bolhuis et al. [22]. The cells were
harvested and washed thrice with 50 mM Hepes buffer, pH 7.3,
containing 25 mM K
#
SO
%
and 5 mM MgSO
%
. Subsequently, the
cells were resuspended in the buffer to a final D
’!!
value of 20.
BCECF-AM (2 mM stock solution in DMSO) was added to the
cell suspension to a final concentration of 1 lM. BCECF
fluorescence was monitored continuously at excitation and
emission wavelengths of 502 and 525 nm respectively, in a
Hitachi F-4500 spectrofluorimeter, equipped with a thermo-
statically controlled (37 °C), magnetically stirred cuvette holder.
RESULTS
Expression and localization of DrrA in E. coli
DrrA was expressed in E. coli BL21(DE3)}pCKB105 at 30 °C at
an IPTG concentration of 100 lM for 4 h (Figure 1A). The
protein localized primarily in the inclusion bodies (results not
shown).
Expression of DrrB in E. coli
Attempts to express DrrB (cloned in the vector pE28a+) in E. coli
BL21(DE3) were abortive. The expressed protein appeared to be
extremely sensitive to proteolysis. DrrB was also cloned in the
vector pBAD-HisA (Invitrogen) under the control of the araBAD
promoter and expressed in E. coli LMG-194. This was done in
view of the fact that the araBAD promoter (pBAD) of E. coli
allows regulated expression, facilitating optimum expression of
protein in its properly folded form. Briefly, transformed cells
were grown up to a D
’!!
of 0.6 in RM-glucose medium with
50 lg}ml ampicillin as described in the Invitrogen pBAD manual.
Cells were induced with 0.002% arabinose at 30 °C for 4 h.
Induced cells were pelleted down, subjected to three cycles of
freezing and thawing, and run on SDS}polyacrylamide (12.5%)
gels. Expressed DrrB migrated as a polypeptide of apparent
molecular mass 31 kDa (Figure 1B). DrrB localized exclusively
to the membranes. However, it still remained sensitive to
proteolytic degradation. Attempts to extract it from membranes
using various detergents were abortive.
Tandem expression of DrrA and DrrB
When E. coli BL21(DE3)}pCKB102 harbouring the drrAB genes
was induced with 50 lM IPTG, the expression of DrrA was
visible on polyacrylamide gels, but the expression of DrrB could
not be visualized. An artificial operon was therefore constructed
to allow the simultaneous expression of DrrA and DrrB. An
artificial ribosome-binding site was introduced upstream of the
drrB gene (Figure 1D), and the drr A and drrB genes were fused
downstream of a hexahistidine-encoding sequence and upstream
of a Myc-epitope-encoding sequence, respectively, in the vector
pET28a+ to give the plasmid pCKB114. Induction of DrrA and
DrrB was found to be optimal when carried out using 50 lM
IPTG at 30 °C for 4 h. Membranes, cytosolic extracts and
inclusion bodies were prepared as described above. In crude cell
extracts, bands corresponding to both DrrA and DrrB were
visible on SDS}polyacrylamide gels. Both DrrA and DrrB
were present exclusively in the membranes of these cells (Fig-
ure 1C, lanes 1 and 2), as confirmed by Western blotting with
anti-His and anti-Myc antibodies (Figure 1C, lanes 3 and 4).
E. coli transformants could be stored as glycerol stocks at
fi70 °C for several weeks without loss of expression of DrrAB.
Expression of DrrAB in M. smegmatis
In order to evaluate the functional characteristics of the DrrAB
efflux pump in mycobacteria, conditions were optimized for
expression of both DrrA and DrrB under the control of the heat-
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Figure 1 Expression of the DrrA and DrrB proteins
Cells were grown and induced as described in the Experimental section. Cells were suspended in Laemmli sample buffer, run on SDS/polyacrylamide (12%) gels and visualized by staining with
Coomassie Blue. (A) DrrA in E. coli BL21(DE3)/pCKB105 ; lanes 1 and 2 represent uninduced and induced cells respectively. (B) DrrB in E. coli LMG194/pCKB109 ; lanes 1–4 represent uninduced
cells, induced cells, and membranes from induced cells and uninduced cells, respectively. (C) Membranes from uninduced (lane 1) and induced (lanes 2–4) E. coli BL21(DE3)/pCKB114 were
run on SDS/polyacrylamide (12%) gels, transferred on to nitrocellulose and either stained with Amido Black (lanes 1 and 2) or probed with anti-His (lane 3) or anti-Myc (lane 4) antibodies.
(D) Schematic representation of the artificial operon constructed for translational coupling and simultaneous expression of DrrA and DrrB. SD, Shine–Dalgarno sequence. (E) Western blots of
M. smegmatis/pCKB115 membranes from uninduced (lanes 1 and 3) and induced (lanes 2 and 4) cells, probed with anti-His (lanes 1 and 2) or anti-Myc (lanes 3 and 4) antibodies.
A
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40020010050
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Figure 2 [a-32P]ATP binding to DrrA
UV-catalysed adduct formation between DrrA and [a-32P]ATP was performed in membrane fractions of cells expressing DrrA and DrrB. Adduct formation was catalysed as described in the
Experimental section. Proteins were resolved on SDS/polyacrylamide (12%) gels, followed by autoradiography. (A) Effect of Mg2+ (5 mM) and varying concentrations of ATP on adduct formation.
(B) Effect of doxorubicin (Dox ; 40 lM) and daunorubicin (Dnr ; 40 lM) on adduct formation carried out in the presence of 5 mM Mg2+ and 200 lM ATP.
shock promoter Hsp60 in M. smegmatis. Heat shock was given
at temperatures ranging from 37 to 45 °C for varying periods of
time (30 min to 2 h). Optimum expression was observed following
heat shock at 42 °C for 45 min. Both components of the pump
localized to the membranes of induced cells as judged by Western
blotting using anti-His and anti-Myc antibodies (Figure 1E).
M. smegmatis transformants could be stored as glycerol stocks
at fi70 °C for 2 weeks, after which transformants showed very
slow growth when cultured in liquid medium.
[a-32P]ATP binding
UV-catalysed binding of [a-$#P]ATP to DrrA was observed when
E. coli membranes expressing DrrA and DrrB were used sim-
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Figure 3 [14C]Doxorubicin accumulation in E. coli (A) and M. smegmatis
(B) expressing DrrA and DrrB
Steady-state accumulation levels of doxorubicin in uninduced (solid bars) cells were taken to
be 100%. Accumulation in uninduced and induced (hatched bars) cells in the absence of
inhibitors was termed controls. Where indicated, induced cells were incubated with 5 lM
doxorubicin and increasing concentrations (lg/ml) of reserpine. Data expressed represent the
means‡S.D. of three separate determinations using three different batches of transformants.
ultaneously for binding studies (Figure 2). The binding was
enhanced in the presence of both doxorubicin and daunorubicin
(Figure 2). It is possible that both these drugs induce a confor-
mational change in DrrA, favouring interaction with ATP.
Uptake of [14C]doxorubicin
["%C]Doxorubicin uptake was studied in E. coli cells harbouring
plasmid pCKB114 designed for tandem expression of DrrA and
DrrB. Doxorubicin was used at a concentration of 5 lM (which
did not affect cell viability). Doxorubicin uptake was significantly
lower in cells induced to express DrrAB compared with un-
induced cells, suggesting that the tandemly expressed DrrA and
DrrB proteins were associating to form a functional doxorubicin
efflux pump (Figure 3A). This was further confirmed by deter-
mining doxorubicin accumulation after addition of reserpine (at
sublethal concentrations), an inhibitor of ATP-dependent efflux
pumps. On addition of reserpine, doxorubicin accumulation in
Figure 4 Uptake of BCECF by cells expressing DrrA and DrrB
BCECF-AM (1 lM) was added to : E. coli BL21(DE3)/pET28a+ energized with glucose (A),
E. coli BL21(DE3)/pCKB114 induced with IPTG and energized with glucose (C) or E. coli
BL21(DE3)/pCKB114 induced with IPTG, energized with glucose and incubated with reserpine
(10 lg/ml ; B).
cells expressing both DrrA and DrrB increased to levels similar
to that observed in uninduced cells. DrrAB therefore appeared to
associate to form a functional doxorubicin efflux pump. Ac-
cumulation levels in cells expressing DrrA or DrrB alone were
similar to uninduced cells (results not shown). The uptake of
doxorubicin in M. smegmatis was again found to be inhibitable
by reserpine (Figure 3B), suggesting that the pump is functional in
M. smegmatis. In E. coli and in M. smegmatis, the difference
in accumulation in the induced and uninduced states while being
statistically significant ranged between 2.5 and 3-fold.
BCECF-AM transport
BCECF-AM is a non-fluorescent, neutral compound which
diffuses across the cytoplasmic membrane. Once inside the cell,
BCECF-AM is rapidly hydrolysed by non-specific esterases,
trapping the non-permeant hydrophilic free acid BCECF within
the cell. BCECF accumulated after the addition of BCECF-AM
to E. coli BL21(DE3)}pET28a+ or to E. coli BL21(DE3)}
pCKB114. Intracellular accumulation was strongly reduced in
the latter case compared with cells containing vector alone. The
expression of DrrAB therefore appeared to play a role in
decreased accumulation of BCECF, suggesting that neutral
compounds may also serve as substrates of the Drr pump.
Addition of reserpine was able to partially restore the level of
accumulation of BCECF to that of cells expressing vector alone
(Figure 4). The likely presence of reserpine-insensitive pump(s) in
E. coliBL21(DE3) probably accounts for the inability of reserpine
to fully restore BCECF accumulation. Cells expressing only
DrrA or DrrB behaved in a manner similar to cells harbouring
the vector pET28a+ or the vector pBAD-HisA alone (results not
shown). The presence of constitutive extracellular mycobacterial
esterases made it impossible to study BCECF accumulation in
M. smegmatis.
Effect of DrrAB expression on drug susceptibility
E. coli BL21(DE3)}pCKB114 expressing DrrA and DrrB sim-
ultaneously showed increased resistance to ethidium bromide,
doxorubicin, daunorubicin, chloramphenicol and puromycin
(Table 1). Cells expressing DrrA or DrrB alone behaved like cells
harbouring the vector pET28a+ or the vector pBAD-HisA alone
(results not shown).
The DrrAB pump is likely involved in the transport of DIM to
the cell surface in M. tuberculosis. In addition, another physio-
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Table 1 Drug susceptibility of cells expressing DrrAB
Both reserpine and verapamil were administered at 10 lg/ml. N.D., not determined.
Drug
MIC of transformants (lg/ml)
E. coli M. smegmatis
Uninduced Induced Uninduced Induced
No inhibitor ›Reserpine ›Verapamil
Ethidium bromide 20 160 3 12 6 6
Daunorubicin 20 40 5 20 5 5
Ethambutol N.D. N.D. 0.5 4 1 0.5
Doxorubicin 20 60 20 60 25 20
Puromycin 20 40 N.D. N.D. N.D. N.D.
Chloramphenicol 1 2 6 36 12 6
Erythromycin N.D. N.D. 10 40 20 10
Norfloxacin N.D. N.D. 2.5 10 5 2.5
Streptomycin N.D. N.D. 1 8 4 4
Tetracycline N.D. N.D. 0.25 4 1 0.25
logical role of such a pump could be to pump out toxic lipophilic
metabolites or hydrophobic compoundswhich are encountered in
the extracellular environment. To address the role of DrrAB
in antibiotic resistance in mycobacteria, the MICs of M. smeg-
matis expressing DrrAB towards a range of clinically relevant
antibiotics were determined. DrrAB conferred resistance to a
broad range of clinically relevant antibiotics, including tetra-
cycline, erythromycin, ethambutol, norfloxacin, streptomycin
and chloramphenicol. This suggested a possible role that it might
play in antibiotic resistance of M tuberculosis.
The differences in the fold enhancement of MICs (in the case
of some drugs) due to the expression of DrrAB observed between
E. coli and M. smegmatis may be attributed to (a) different roles
of the permeability barrier, (b) roles of other efflux pumps,
(c) differences in target sensitivities and (d) different drug-
inactivating mechanisms in the two organisms.
DISCUSSION
The principal physiological role of the Drr proteins of M. tuber-
culosis appears to be in the export of complex lipids to the
cell exterior. The role of ABC transporters in lipid transport is
now being acknowledged widely [23]. The role of the drr operon
in transport of DIM to the cell surface in M. tuberculosis has also
been documented [15]. The results of drug susceptibility profiling
in the E. coli and M. smegmatis expression systems for DrrAB
developed by us suggest a role of this pump in resistance against
hydrophobic drugs. The attempts to express the two proteins in-
dividually in E. coli suggest that neither of the two proteins
retains its integrity in the absence of the other protein. DrrB
appeared to be exquisitely sensitive to proteolysis in the absence
of DrrA. The use of the artificial operon to achieve simultaneous
expression of DrrA and DrrB allows the demonstration of the
interdependence of the two proteins. The targeting of DrrA to
the membranes is facilitated by the co-expression of DrrB,
while the stability of DrrB in the membranes is facilitated by
the simultaneous presence of DrrA in the membranes.
In E. coli, both cationic hydrophobic compounds such as
doxorubicin and neutral compounds such as BCECF appeared
to be substrates of the functional DrrAB efflux pump. The
expression of the pump in E. coli imparted 8-fold increased
resistance to ethidium bromide, a cationic substrate of ABC
transporters. Increased adduct formation with [a-$#P]ATP in the
presence of doxorubicin or daunorubicin raised the possibility
that substrate binding to the pump induces a conformational
alteration favouring ATP binding to DrrA. This is similar to the
observation that doxorubicin stimulates ATP binding to DrrA of
S. peucetius [24]. Whether it does so by binding to a site in the
DrrA protein or exerts an indirect effect after binding to DrrB is
open to question. Drug-stimulated ATPase activity has been
reported in the case of the human P-glycoprotein [25]. The
overexpression of a functional doxorubicin efflux pump from
M. tuberculosis and its inhibition by known inhibitors of ABC
transporters, such as reserpine, exemplifies the characterization
of an ABC transporter for the first time from this globally
important pathogen, and demonstrates that it imparts resistance
to hydrophobic drugs. The use of doxorubicin accumulation to
determine functionality of the DrrAB pump provides an assay
system for biochemical characterization of this pump. The
difference in accumulation levels between induced and uninduced
cells ranges between 2.5- and 3-fold in E. coli and M. smegmatis.
This suggests that only inhibitors that inhibit the pump almost
completely are likely to be picked up without ambiguity using
this assay system. Similarly, the effects of mutations of conserved
amino acid residues are likely to be reflected unambiguously
when such mutations inhibit the pump almost completely.
Nevertheless, the expression systems described here deserve
further evaluation considering that development of an assay
system based on the likely natural substrate DIM appears even
more technically challenging and elusive.
The differences in MIC observed in M. smegmatis expressing
DrrAB suggest that this pump confers resistance towards a
broad range of structurally unrelated drugs in mycobacteria.
This is like the observation that LmrA, the Lactococcus lactis
counterpart of the human P-glycoprotein, shows broad substrate
specificity [26]. The M. smegmatis assay system is likely to be
useful in evaluating drugs of potential against mycobacteria by
virtue of their ability to inhibit DrrAB. On the other hand, the
E. coli expression system is more robust ; with E. coli transfor-
mants being more stable than M. smegmatis transformants when
stored as glycerol stocks at fi70 °C. E. coli also has the advantage
of a faster generation time than M. smegmatis.
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